Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Lenalidomide in Treating Patients with Castration-Resistant Prostate Cancer

  • Xing, Dong-Liang (Department of Urology, the Fifth Affiliated Hospital of Zhengzhou University) ;
  • Song, Dong-Kui (Department of Urology, the First Affiliated Hospital of Zhengzhou University) ;
  • Zhang, Li-Rong (Department of Pharmacogenetics, the Medical College of Zhengzhou University)
  • Published : 2015.05.18
Download PDF
⟨ Previous Next ⟩

Abstract

Background: This analysis was conducted to evaluate the efficacy and safety of lenalidomide based regimen in treating patients with castration-resistant prostate cancer. Materials and Methods: Clinical studies evaluating the efficacy and safety of lenalidomide based regimens on response and safety for patients with castration-resistant prostate cancer were identified using a predefined search strategy. A pooled response rate (rate of PSA level decline of ${\geq}50%$) to treatment was calculated. Results: In lenalidomide based regimen, 3 clinical studies which including 98 patients with castration-resistant prostate cancer were considered eligible for inclusion. These lenalidomide based regimens included cisplatin, doxorubicin, or GM-CSF. Pooled analysis suggested that, in all patients, the pooled PSA level decline of ${\geq}50%$ was 13.3% (13/98) in lenalidomide based regimens. Fatigue, nausea and vomitting were the main side effects. No grade III or IV renal or liver toxicity were observed. No treatment related death occurred in patients with lenalidomide based regimens. Conclusions: This evidence based analysis suggests that lenalidomide based regimens are associated with mild response rate and acceptable toxicities for treating patients with castration-resistant prostate cancer.

Keywords

References

  1. Baker SD, Zhao M, Lee CK, et al (2004). Comparative pharmacokinetics of weekly and every-three-weeks docetaxel. Clin Cancer Res, 10, 1976-83. https://doi.org/10.1158/1078-0432.CCR-0842-03
  2. Berry W, Dakhil S, Gregurich MA (2001). Asmar L Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol, 28, 8-15. https://doi.org/10.1053/sonc.2001.26893
  3. de Bono JS, Logothetis CJ, Molina A, et al (2011). Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med, 364, 1995-2005. https://doi.org/10.1056/NEJMoa1014618
  4. de Bono JS, Oudard S, Ozguroglu M, et al (2010). Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet, 376, 1147-54. https://doi.org/10.1016/S0140-6736(10)61389-X
  5. Du LB, Li HZ, Wang XH, et al (2014). Analysis of cancer incidence in Zhejiang cancer registry in China during 2000 to 2009. Asian Pac J Cancer Prev, 15, 5839-43. https://doi.org/10.7314/APJCP.2014.15.14.5839
  6. Ferrero JM, Foa C, Thezenas S, et al (2004). A weekly schedule of docetaxel for metastatic hormone-refractory prostate cancer. Oncology, 66, 281-7. https://doi.org/10.1159/000078328
  7. Messing EM, Manola J, Sarosdy M, et al (1999). Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med, 341, 1781-8. https://doi.org/10.1056/NEJM199912093412401
  8. de Bono JS, Oudard S, Ozguroglu M, et al (2010). Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet, 376, 1147-54. https://doi.org/10.1016/S0140-6736(10)61389-X
  9. Garcia JA, Elson P, Tyler A, et al (2014). Sargramostim (GMCSF) and lenalidomide in castration-resistant prostate cancer (CRPC): results from a phase I-II clinical trial. Urol Oncol, 32, 11-7.
  10. Hurria A, Fleming MT, Baker SD, et al (2006). Pharmacokinetics and toxicity of weekly docetaxel in older patients. Clin Cancer Res, 12, 6100-5. https://doi.org/10.1158/1078-0432.CCR-06-0200
  11. Kantoff PW, Higano CS, Shore ND, et al (2010). Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med, 363, 411-22. https://doi.org/10.1056/NEJMoa1001294
  12. Keizman D, Zahurak M, Sinibaldi V, et al (2010). Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study. Clin Cancer Res, 16, 5269-76. https://doi.org/10.1158/1078-0432.CCR-10-1928
  13. Kellokumpu-Lehtinen PL, Harmenberg U, Joensuu T, et al (2013). 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol, 14, 117-24. https://doi.org/10.1016/S1470-2045(12)70537-5
  14. Luo HC, Cheng HH, Lin GS, et al (2013). Intensity-modulated radiotherapy combined with endocrine therapy for intermediate and advanced prostate cancer: long-term outcome of Chinese patients. Asian Pac J Cancer Prev, 14, 4711-5. https://doi.org/10.7314/APJCP.2013.14.8.4711
  15. Nabhan C, Petrylak DP (2012). The role of IMiDs alone or in combination in prostate cancer. Clin Genitourin Cancer, 10, 141-6. https://doi.org/10.1016/j.clgc.2012.03.005
  16. Nabhan C, Patel A, Villines D, et al (2014). Lenalidomide monotherapy in chemotherapy-naive, castration-resistant prostate cancer patients: final results of a phase II study. Clin Genitourin Cancer, 12, 27-32. https://doi.org/10.1016/j.clgc.2013.09.001
  17. Nelson WG, De Marzo AM, Isaacs WB (2003). Prostate cancer. N Engl J Med, 349, 366-81. https://doi.org/10.1056/NEJMra021562
  18. Parker C, Nilsson S, Heinrich D, et al (2013). Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med, 369, 213-23. https://doi.org/10.1056/NEJMoa1213755
  19. Pazdur R (2013). FDA Approval for Docetaxel. Available:http://www.cancer.gov/cancertopics/druginfo/fda-docetaxel.
  20. Petrylak DP, Tangen CM, Hussain MH, et al (2004). Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med, 351, 1513-20. https://doi.org/10.1056/NEJMoa041318
  21. Scher HI, Fizazi K, Saad F, et al (2012). Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med, 367, 1187-97. https://doi.org/10.1056/NEJMoa1207506
  22. Siegel R, Naishadham D, Jemal A (2013). Cancer statistics, 2013. CA Cancer J Clin, 63, 11-30. https://doi.org/10.3322/caac.21166